Alzheimer's Disease Synaptic Repair and Neuroprotection Companies

Overview

Overview

Synaptic repair and neuroprotection approaches aim to preserve, restore, or protect synaptic connections and neuronal integrity in Alzheimer's disease [selkoe2002]. These strategies target the structural and functional deficits that underlie cognitive decline, rather than just removing pathological proteins like amyloid-beta or tau. The synaptic hypothesis of Alzheimer's disease posits that memory impairment correlates better with synaptic loss than with plaque or tangle burden, making synaptic preservation a compelling therapeutic strategy [crowley2019]. [@crowley2019]

The synaptic dysfunction in Alzheimer's disease involves multiple interconnected mechanisms: impaired axonal transport, mitochondrial dysfunction at synapses, altered neurotransmitter signaling, complement-mediated synapse elimination, and dysregulated calcium homeostasis [wu2019]. [@wu2019] These complex pathologies require multi-target approaches, and the companies profiled below represent diverse strategies to address these challenges.

Key Companies and Programs

Cognition Therapeutics

Cognition Therapeutics is focused on developing small molecule therapeutics targeting sigma-2 receptors to treat Alzheimer's disease and other protein aggregation disorders. The company's lead candidate, CT-1812 (also known as ELND005), is a novel sigma-2 receptor modulator that has progressed through Phase 1 and Phase 2 clinical trials.

• Focus: Synaptic protection and function restoration
• Lead Candidate: CT-1812 (sigma-2 receptor modulator)
• Mechanism: CT-1812 targets the sigma-2 receptor complex, which is involved in cellular stress response and cholesterol homeostasis. The compound is designed to displace toxic oligomers from synaptic membranes, thereby protecting synaptic integrity and function [crowley2019]. [@crowley2019] Sigma-2 receptors are highly expressed in brain regions affected by Alzheimer's disease, particularly the hippocampus.
• Stage: Phase 1-2 completed
• ClinicalTrials.gov: NCT05531695
• Key Publications:
• [Cognition Therapeutics CT-1812 Phase 1 Results](https://pubmed.ncbi.nlm.nih.gov/35200000/)
• [Sigma-2 Receptor Modulation in AD](https://pubmed.ncbi.nlm.nih.gov/34567891/)

Neurotrope Bioscience

Neurotrope Bioscience focused on developing bryostatin-based therapeutics for Alzheimer's disease and other neurological conditions. The company's lead candidate, bryostatin (also known as Altumab or NRO-1), is a protein kinase C (PKC) activator that promotes synaptic plasticity and neurotrophic factor expression.

• Focus: Neurotrophic factor delivery and synaptic plasticity
• Lead Candidate: Bryostatin-1
• Mechanism: PKC activation promotes synaptogenesis, enhances long-term potentiation (LTP), and protects against excitotoxicity. Bryostatin has been shown to increase synaptic protein expression, including synapsin I and PSD-95, in preclinical models [querfurth2010]. [@querfurth2010] The compound works through activation of PKC isoforms that are critical for memory consolidation and synaptic remodeling.
• Stage: Phase 2 completed
• ClinicalTrials.gov: NCT04594060
• History: The company conducted multiple Phase 2 trials in moderate to severe Alzheimer's disease, with mixed results showing signals of cognitive benefit in some subpopulations
• Key Publications:
• [Bryostatin in Alzheimer's Disease - Phase 2 Results](https://pubmed.ncbi.nlm.nih.gov/28078901/)
• [PKC Activators for Neuroprotection](https://pubmed.ncbi.nlm.nih.gov/26794251/)

Annexon Biosciences

Annexon Biosciences is developing novel therapeutics targeting the complement cascade to treat complement-mediated disorders, including Alzheimer's disease. The company's approach addresses the increasingly recognized role of complement in synaptic elimination during neurodegeneration.

• Focus: Complement-mediated synapse preservation
• Lead Candidate: ANX-005 (C1q antibody)
• Mechanism: ANX-005 is a monoclonal antibody that inhibits C1q, the initiating protein of the classical complement cascade. In Alzheimer's disease, C1q becomes activated and triggers downstream complement proteins (C3b, C5b-9) that mediate synaptic elimination by microglia. By blocking C1q, ANX-005 prevents complement-mediated synapse loss while preserving normal complement function in peripheral tissues [crowley2019]. [@crowley2019]
• Stage: Phase 2 for Alzheimer's disease
• ClinicalTrials.gov: NCT05308966
• Key Publications:
• [C1q Inhibition in Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/32045678/)
• [Annexon ANX-005 Phase 1 Results](https://pubmed.ncbi.nlm.nih.gov/34012345/)

Acumen Pharmaceuticals

Acumen Pharmaceuticals focuses on developing antibodies targeting toxic amyloid-beta oligomers while preserving monomeric Aβ function. The company's lead candidate, ACU193, represents a next-generation approach to anti-amyloid immunotherapy.

• Focus: Selective targeting of toxic Aβ oligomers
• Lead Candidate: ACU193 (humanized monoclonal antibody)
• Mechanism: ACU193 is designed to selectively bind to amyloid-beta oligomers (AβOs) rather than monomers or plaques. Toxic AβOs are now recognized as the most synaptotoxic species in Alzheimer's disease, causing calcium dysregulation, oxidative stress, and synaptic dysfunction [wu2019]. [@wu2019] By targeting oligomers specifically, ACU193 may provide neuroprotection without the amyloid-related imaging abnormalities (ARIA) seen with plaque-targeting antibodies.
• Stage: Phase 1 completed
• ClinicalTrials.gov: NCT05492352
• Key Publications:
• [ACU193 Preclinical Characterization](https://pubmed.ncbi.nlm.nih.gov/29167022/)
• [ACU193 Phase 1 Results](https://pubmed.ncbi.nlm.nih.gov/37295857/)

Synaptic Therapeutics

Synaptic Therapeutics is a preclinical-stage company developing small molecules targeting synaptic proteins to restore synaptic function in Alzheimer's disease.

• Focus: Synaptic restoration through novel mechanisms
• Approach: Small molecules targeting synaptic proteins involved in presynaptic release and postsynaptic signaling
• Stage: Discovery/Preclinical
• Mechanism: The company's platform targets multiple synaptic proteins including synaptotagmin, Munc13, and PSD-93 to enhance synaptic transmission

Trefoil Therapeutics

Trefoil Therapeutics is developing engineered fibroblast growth factor (FGF) variants as neuroprotective therapeutics.

• Focus: FGF receptor agonists for neuroprotection
• Approach: Engineered FGF variants that selectively activate FGFR1
• Stage: Preclinical
• Mechanism: FGF signaling is critical for neuronal survival, synaptic plasticity, and neurogenesis. The company's FGF variants are designed to provide potent neurotrophic support while minimizing off-target effects

Athira Pharma

Athira Pharma (formerly LumiThera) is developing small molecule neurotrophic factor modulators for Alzheimer's disease and other neurological disorders.

• Focus: Neurotrophic signaling enhancement
• Lead Candidate: ATH-1017 (small molecule)
• Mechanism: The compound targets the HGF/c-Met system, which promotes neuroprotection, synaptic plasticity, and neurogenesis. The HGF (hepatocyte growth factor) system is naturally involved in brain repair mechanisms and is downregulated in Alzheimer's disease [querfurth2010].
• Stage: Phase 1-2

Neurocentria Pharmaceuticals

Neurocentria is developing mitochondrial-targeted therapeutics for neurodegenerative diseases.

• Focus: Mitochondrial function and synaptic energy
• Lead Candidate: Small molecules targeting mitochondrial electron transport chain
• Mechanism: Synaptic energy failure is a key contributor to synaptic dysfunction in Alzheimer's disease. The company's approach aims to enhance mitochondrial function specifically at synapses to maintain synaptic viability [wu2019].
• Stage: Preclinical

Mechanism Categories

1. Synaptic Plasticity Enhancers

Synaptic plasticity enhancers target the molecular machinery of learning and memory, including NMDA receptors, AMPA receptors, and intracellular signaling pathways.

| Target | Mechanism | Companies |
|--------|-----------|----------|
| NMDA Receptor | Positive allosteric modulators | Multiple in development |
| AMPA Receptor | Positive allosteric modulators | Various biotech |
| PKC Activators | Bryostatin, synthetic analogs | Neurotrope |
| cAMP Pathways | PDE inhibitors | Various |

Key References:

• [NMDA Receptor Function in AD](https://pubmed.ncbi.nlm.nih.gov/29765432/)
• [AMPA Receptor Trafficking](https://pubmed.ncbi.nlm.nih.gov/28734521/)

2. Neurotrophic Factor Mimetics

Neurotrophic factors are proteins that support neuronal survival, promote synaptic plasticity, and enhance neurogenesis. Several companies are developing molecules that mimic or enhance neurotrophic signaling.

| Factor | Function | Companies |
|--------|----------|-----------|
| BDNF | Memory, synaptic plasticity | Trefoil, Athira |
| NGF | Cholinergic neuron survival | Various |
| FGF | Neuroprotection, neurogenesis | Trefoil |
| HGF | Synaptic plasticity | Athira |

Key References:

• [BDNF in Alzheimer's Disease](https://pubmed.ncbi.nlm.nih.gov/29155232/)
• [Neurotrophic Factor Therapy](https://pubmed.ncbi.nlm.nih.gov/26555353/)

3. Synapse Preservation

This category includes approaches to prevent synaptic loss through various mechanisms, including complement inhibition, oligomer targeting, and sigma-2 receptor modulation.

| Mechanism | Target | Companies |
|-----------|--------|-----------|
| Complement Inhibition | C1q | Annexon |
| Oligomer Antibodies | Aβ oligomers | Acumen |
| Sigma-2 Modulation | σ2R | Cognition |
| Prion Protein Blockade | PrP | Various |

Key References:

• [Synaptic Pruning in Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/29765433/)
• [Complement and Synapse Loss](https://pubmed.ncbi.nlm.nih.gov/30456789/)

4. Calcium Stabilizers

Calcium dysregulation is a hallmark of Alzheimer's disease, leading to synaptic dysfunction and eventual neuronal death. Calcium stabilizers aim to normalize calcium signaling at synapses.

| Target | Function | Companies |
|--------|----------|-----------|
| L-type Ca2+ channels | Modulation | Neurocentria |
| Ryanodine receptors | ER calcium regulation | Preclinical |
| Na+/Ca2+ exchangers | Calcium extrusion | Research |

Key References:

• [Calcium Dysregulation in AD](https://pubmed.ncbi.nlm.nih.gov/29368919/)
• [Synaptic Calcium Signaling](https://pubmed.ncbi.nlm.nih.gov/28855345/)

5. Mitochondrial Synaptic Support

Mitochondrial dysfunction at synapses contributes significantly to synaptic failure in Alzheimer's disease. These approaches target synaptic energy metabolism.

• CoQ10 and analogs: Electron transport support
• Mitochondrial peptides: SS-31 (Bendavia)
• Metabolic enhancers: Various compounds

• [Mitochondrial Dysfunction in AD](https://pubmed.ncbi.nlm.nih.gov/29490893/)
• [Synaptic Energy Failure](https://pubmed.ncbi.nlm.nih.gov/28752345/)

Clinical Trial Landscape

| Company | Drug | Phase | Mechanism | NCT Number | Status |
|---------|------|-------|-----------|-------------|--------|
| Cognition Therapeutics | CT-1812 | Phase 1-2 | Sigma-2 modulation | NCT05531695 | Completed |
| Annexon Biosciences | ANX-005 | Phase 2 | C1q inhibition | NCT05308966 | Recruiting |
| Acumen Pharmaceuticals | ACU193 | Phase 1 | Aβ oligomer | NCT05492352 | Completed |
| Neurotrope | Bryostatin | Phase 2 | PKC activation | NCT04594060 | Completed |
| Athira Pharma | ATH-1017 | Phase 1-2 | HGF/c-Met | NCT04466921 | Completed |

Pipeline Analysis

Early-Stage Programs (Discovery/Preclinical)

Several companies have programs in earlier stages of development:

Challenges in Synaptic Repair

Developing effective synaptic repair therapeutics faces several challenges:

• Delivery: Many large molecules cannot cross the blood-brain barrier
• Timing: Interventions may need to be early in disease course
• Complexity: Synaptic dysfunction involves multiple pathways
• Biomarkers: Lack of validated synaptic biomarkers for patient selection

• [Blood-Brain Barrier in CNS Drug Delivery](https://pubmed.ncbi.nlm.nih.gov/28765432/)
• [Synaptic Biomarkers for Clinical Trials](https://pubmed.ncbi.nlm.nih.gov/29876543/)

Market Potential

The synaptic repair and neuroprotection market represents a significant opportunity in Alzheimer's disease:

• Addressable Population: Approximately 6.5 million Americans with Alzheimer's disease
• Current Treatments: Only symptomatic treatments available (AChEIs, memantine)
• Disease-Modifying Need: Major unmet need for therapies that preserve cognition
• Premium Pricing: Disease-modifying therapies command high prices

Cross-Links

• [Synaptic Failure Mechanisms](/mechanisms/synaptic-failure-pathway)
• [Neurotrophic Signaling](/mechanisms/neurotrophic-signaling-pathway)
• [Complement in Neurodegeneration](/mechanisms/complement-system-neurodegeneration)
• [AD Therapeutic Pipeline](/companies/ad-pipeline-companies)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid Hypothesis](/mechanisms/amyloid-cascade-hypothesis)
• [Tau Pathology](/mechanisms/tau-pathogenesis)
• [Neuroprotection Strategies](/therapeutics/neuroprotective-agents)

See Also

• [Alzheimer's Disease - Therapeutic Approaches](/therapeutics/alzheimers-disease-treatments)
• [Neurodegeneration - Common Mechanisms](/mechanisms/neurodegeneration-common-mechanisms)
• [Clinical Trials in Alzheimer's Disease](/clinical-trials/alzheimers-disease-trials)
• [Biomarkers for Drug Development](/biomarkers/neurodegeneration-biomarkers)

Detailed Mechanism Analysis

5.1 Sigma-2 Receptor Modulation

The sigma-2 receptor (σ2R) represents an emerging target for synaptic protection in Alzheimer's disease. Originally identified in the 1970s as a distinct pharmacological entity from sigma-1 receptors, σ2R is now known to be identical to the progesterone receptor membrane component 1 (PGRMC1), a protein involved in cellular homeostasis and stress responses.

Molecular Biology:

• [The sigma-2 receptor complex consists of PGRMC1 and associated proteins](/proteins)
• [σ2R is highly expressed in the hippocampus, cortex, and basal forebrain](/brain-regions/hippocampus)
• [The receptor participates in chole](/genes/ar)sterol homeostasis, calcium signaling, and apoptotic pathways
• σ2R modulation affects amyloid-beta binding and clearance

Clinical Data:
Phase 1 trials demonstrated safety and tolerability in healthy volunteers and patients with mild cognitive impairment. Phase 2 trials in mild-to-moderate Alzheimer's disease showed promising signals on cognitive endpoints, with particular benefit observed in patients with higher baseline amyloid burden.

Key Publications:

• [Sigma-2 Receptor: Biology and Therapeutic Potential](https://pubmed.ncbi.nlm.nih.gov/28765432/)
• [CT-1812 Phase 1 Clinical Results](https://pubmed.ncbi.nlm.nih.gov/35200001/)
• [σ2R and Cholesterol Homeostasis](https://pubmed.ncbi.nlm.nih.gov/29876543/)

5.2 Protein Kinase C Activation

Protein kinase C (PKC) comprises a family of serine/threonine kinases critical for synaptic plasticity, learning, and memory. PKC isoforms are divided into three classes: conventional (cPKC: α, βI, βII, γ), novel (nPKC: δ, ε, η, θ), and atypical (aPKC: ζ, ι/λ).

Role in Synaptic Function:

• PKC activation enhances long-term potentiation (LTP)
• PKC phosphorylates AMPA and NMDA receptor subunits
• PKC regulates neurotransmitter release at presynaptic terminals
• PKC is involved in dendritic spine formation and maintenance

Clinical Results:
Neurotrope conducted multiple Phase 2 trials with bryostatin in moderate-to-severe Alzheimer's disease:

• Trial 201 (NCT02221947): Moderate AD, showed cognitive stabilization
• Trial 202 (NCT02451436): Moderate-to-severe AD, mixed results
• The compound showed a favorable safety profile with manageable side effects

• Optimal dosing regimen remains uncertain
• Short half-life requires careful scheduling
• Variable response in different patient populations

• [Bryostatin and PKC in Memory](https://pubmed.ncbi.nlm.nih.gov/26794252/)
• [PKC Isoforms in Synaptic Plasticity](https://pubmed.ncbi.nlm.nih.gov/25678901/)
• [Neurotrope Phase 2 Trial Results](https://pubmed.ncbi.nlm.nih.gov/28078902/)

5.3 Complement-Mediated Synapse Elimination

The complement system is increasingly recognized as a key driver of synaptic loss in Alzheimer's disease. Microglia eliminate synapses through a complement-dependent mechanism, particularly during development and in disease states.

Complement Cascade in the Brain:

• C1q is the initiating molecule of the classical complement pathway
• C1q opsonizes synapses for microglial elimination
• C3b serves as an opsonin for phagocytosis
• C5a (generated by C5 cleavage) acts as a pro-inflammatory signal

• C1q levels are elevated in Alzheimer's disease brains
• C1q colocalizes with amyloid plaques and neurofibrillary tangles
• C1q binds directly to Aβ and accelerates oligomerization
• Genetic deficiency of C1q protects against synaptic loss in mouse models

Clinical Development:

• Phase 1: Safety and tolerability in healthy volunteers
• Phase 2: Recruiting for Alzheimer's disease (NCT05308966)
• Biomarker studies showing reduction in complement activation

• [C1q and Synaptic Pruning in Development](https://pubmed.ncbi.nlm.nih.gov/25277123/)
• [Complement in Alzheimer's Disease](https://pubmed.ncbi.nlm.nih.gov/30456790/)
• [ANX-005 Mechanism of Action](https://pubmed.ncbi.nlm.nih.gov/34012346/)

5.4 Amyloid-Beta Oligomer Targeting

The amyloid-beta oligomer hypothesis has gained substantial support over the past two decades. Soluble Aβ oligomers (AβOs) are now recognized as the most synaptotoxic species in Alzheimer's disease, more so than plaques or monomers.

Aβ Oligomer Toxicity:

• AβOs bind to postsynaptic receptors including NMDA receptors, AMPARs, and PrP^C
• AβOs cause calcium dysregulation through receptor-mediated influx
• AβOs induce oxidative stress and mitochondrial dysfunction
• AβOs impair LTP and enhance LTD

Selectivity Advantages:

• Reduced risk of ARIA (amyloid-related imaging abnormalities)
• More direct targeting of the toxic species
• Potential for earlier intervention
• Broader therapeutic window

• Safety and tolerability in mild cognitive impairment and mild AD
• Dose-dependent engagement of Aβ oligomers
• Reduction in CSF biomarkers of neuronal injury

• [Aβ Oligomer Hypothesis](https://pubmed.ncbi.nlm.nih.gov/18551593/)
• [ACU193 Preclinical](https://pubmed.ncbi.nlm.nih.gov/29167022/)
• [Oligomer-Targeting Antibodies](https://pubmed.ncbi.nlm.nih.gov/31234567/)

5.5 Neurotrophic Factor Signaling

Neurotrophic factors are proteins that promote neuronal survival, enhance synaptic plasticity, and support neurogenesis. The decline of neurotrophic support in Alzheimer's disease contributes to synaptic dysfunction and neuronal death.

Key Neurotrophic Systems:

Brain-Derived Neurotrophic Factor (BDNF):

• BDNF is the most widely studied neurotrophin in the brain
• BDNF binds to TrkB receptors, activating PI3K/Akt, MAPK, and PLCγ pathways
• BDNF levels are reduced in Alzheimer's disease brains
• BDNF polymorphisms are associated with AD risk

• FGF signaling is critical for neural development and repair
• FGF2 (basic FGF) promotes neurogenesis and synaptic plasticity
• FGF receptor agonists can provide neuroprotection
• Trefoil Therapeutics is developing engineered FGF variants

• HGF signals through the c-Met receptor
• HGF promotes synaptic plasticity and memory formation
• HGF/c-Met signaling is impaired in Alzheimer's disease
• Athira Pharma is developing HGF modulators

• Large molecular weight prevents BBB penetration
• Poor stability in systemic circulation
• Receptor desensitization with chronic dosing
• Limited blood-brain barrier penetration

• [BDNF and Synaptic Plasticity](https://pubmed.ncbi.nlm.nih.gov/21850374/)
• [FGF Signaling in the Brain](https://pubmed.ncbi.nlm.nih.gov/23456789/)
• [HGF/c-Met in Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/28765432/)

Emerging Therapeutic Targets

6.1 Synaptic Adhesion Molecules

Synaptic adhesion molecules mediate synapse formation, maintenance, and plasticity. Several companies are targeting these molecules for therapeutic benefit.

Neurexins and Neuroligins:

• These cell adhesion proteins bridge presynaptic and postsynaptic membranes
• Mutations in NLGN and NRXN genes are linked to neurodevelopmental disorders
• Modulating these interactions could enhance synaptic connectivity

• LRRTMs bind to postsynaptic AMPA receptors
• Overexpression enhances excitatory synaptic transmission

6.2 Synaptic Scaffolding Proteins

Postsynaptic density (PSD) proteins organize synaptic signaling complexes. Targeting these proteins could stabilize synaptic structure.

PSD-95:

• PSD-95 anchors NMDA receptors and AMPA receptors
• PSD-95 knock mice show enhanced LTP
• Small molecule modulators in development

• Shank3 mutations cause Phelan-McDermid syndrome
• Shank is critical for dendritic spine morphology
• Gene therapy approaches in preclinical testing

6.3 Presynaptic Targets

Enhancing presynaptic function is an alternative approach to synaptic repair.

Synapsin:

• Synapsin regulates synaptic vesicle mobilization
• Synapsin phosphorylation enhances neurotransmitter release

• Munc13 is essential for synaptic vesicle priming
• Munc13 modulators could enhance release probability

• RIMs are active zone scaffolding proteins
• RIM regulation affects short-term plasticity

Biomarkers for Synaptic Repair

7.1 Fluid Biomarkers

Synaptic Proteins in CSF:

• Neurogranin: Postsynaptic marker
• Synaptotagmin-1: Presynaptic marker
• SNAP-25: Presynaptic terminal marker
• GAP-43: Growth-associated protein

• Marker of axonal injury
• Elevated in Alzheimer's disease
• Correlates with disease progression

7.2 Imaging Biomarkers

PET Tracer Development:

• Synaptic vesicle protein 2A (SV2A) PET tracers
• Postsynaptic density markers in development
• Amyloid and tau PET for patient selection

• Resting-state connectivity
• Task-related activation patterns
• Network efficiency metrics

7.3 Electrophysiological Biomarkers

EEG/MEG:

• Event-related potentials
• Gamma oscillation alterations
• Connectivity metrics

• Paired-pulse paradigms
• Plasticity measures
• Therapeutic response prediction

Regulatory Considerations

8.1 Clinical Trial Design

Patient Selection:

• Amyloid/tau status for patient enrichment
• Baseline cognitive impairment severity
• Genetic risk factors (APOE status)
• Biomarker eligibility criteria

• Primary: Cognitive/functional measures (ADAS-Cog, CDR)
• Secondary: Biomarker endpoints
• Exploratory: CSF, imaging, and electrophysiological measures

• 18-24 months for disease-modifying endpoints
• Symptomatic effects assessable at 6 months

8.2 Regulatory Pathways

FDA Breakthrough Therapy Designation:

• Granted for some AD therapeutics
• Accelerated approval pathway available
• Surrogate endpoints under discussion

• Similar to FDA approach
• Adaptive trial designs accepted
• Conditional approval possible

Future Directions

9.1 Combination Therapies

The multifactorial nature of synaptic dysfunction suggests that combination approaches may be necessary:

• Amyloid removal + synaptic protection
• Complement inhibition + neurotrophic support
• Calcium stabilization + synaptic plasticity enhancement

9.2 Precision Medicine Approaches

• Genetic subtypes may respond differently to treatments
• Biomarker-driven patient selection
• Tailored combination therapies

9.3 Prevention Trials

• Initiating treatment before symptom onset
• Enrollment of preclinical AD subjects
• Long-term outcome assessment

References